Ultragenyx Earnings Reports

Ultragenyx delivered $164,877,000 in revenue for Q4 2024, a 29% YoY increase, primarily fueled by Crysvita and Dojolvi sales. Despite higher revenue, the company reported a net loss of $133,385,000, with increased R&D and operating expenses.

Ultragenyx reported a strong third quarter with a 42% increase in total revenue, reaching $139 million. Crysvita revenue grew by 31% to $98 million, and Dojolvi revenue increased by 29% to $21 million. The company reaffirmed its 2024 total revenue guidance of $530 million to $550 million and highlighted clinical advancements, including Breakthrough Therapy Designation for setrusumab.

Ultragenyx reported a strong second quarter in 2024, with total revenue reaching $147 million, a 36% increase compared to the same period in 2023. The company raised its total revenue guidance for 2024 to $530 million to $550 million. Positive data was reported from Phase 1/2, Phase 2/3, and Phase 3 studies.

Ultragenyx reported $109 million in total revenue for the first quarter of 2024, representing 8% growth compared to the same period in 2023. Crysvita revenue was $83 million, a 9% increase year-over-year, while Dojolvi revenue was $16 million, a 14% increase year-over-year. The company reaffirmed its full-year 2024 revenue guidance.

Ultragenyx reported a 23% increase in total revenue for Q4 2023, reaching $127 million. The company saw growth in Crysvita and Dojolvi sales. They are focused on advancing their Phase 3 programs and executing commercial product launches.

Ultragenyx reported $98.1 million in total revenue for the third quarter 2023, representing 8% growth compared to the third quarter 2022. The company reaffirmed its 2023 expected total revenue guidance between $425 million to $450 million.

Ultragenyx reported a total revenue of $108.3 million for the second quarter of 2023, representing a 21% increase compared to the second quarter of 2022. Crysvita revenue in North America grew by 19% to $61.3 million. The company reaffirmed its 2023 total revenue guidance between $425 million and $450 million.

Ultragenyx reported a 26% increase in total revenue for Q1 2023, driven by Crysvita and Dojolvi. The company is progressing with clinical programs, including UX143 and GTX-102, and reaffirms its 2023 revenue guidance.

Ultragenyx reported Q4 2022 total revenue of $103.3 million. The company reaffirmed its 2023 financial guidance, expecting total revenue between $425 million and $450 million and net cash used in operations to be less than $400 million.

Ultragenyx reported a total revenue of $90.7 million for Q3 2022, with Crysvita revenue in Ultragenyx territories reaching $64.5 million. The company reaffirmed its 2022 revenue guidance for Crysvita and Dojolvi. Enrollment completion of DTX401 Phase 3, UX143 Phase 2, and GTX-102 dose escalation cohorts is anticipated around the end of the year.

Ultragenyx reported second quarter revenue of $89.3 million, including $64.0 million from Crysvita and $13.5 million from Dojolvi. They completed the sale of a capped 30% royalty interest on future Crysvita sales for $500 million and acquired GeneTx. The company reaffirmed its 2022 revenue guidance for Crysvita and Dojolvi.

Ultragenyx reported a total revenue of $79.9 million for the first quarter of 2022. The company reaffirmed its 2022 revenue guidance for Crysvita and Dojolvi.

Ultragenyx reported a total revenue of $83.4 million for Q4 2021. The company made significant progress across its early and late-stage clinical pipeline and is preparing for the launch of Evkeeza in Europe.

Ultragenyx reported third quarter 2021 financial results, with total revenue of $81.6 million. Crysvita revenue in Ultragenyx territories increased 35% compared to the third quarter of 2020. The company is preparing to initiate four additional studies across multiple modalities.

Ultragenyx reported a total revenue of $87.0 million for the second quarter of 2021, which includes $44.7 million from Crysvita. The company reaffirmed its 2021 guidance for Crysvita revenue in Ultragenyx territories to be between $180 million and $190 million.

Ultragenyx reported a total revenue of $99.4 million for the first quarter of 2021, with Crysvita revenue reaching $42.1 million. The company reaffirmed its 2021 Crysvita revenue guidance of $180 million to $190 million. Dojolvi launch continues with approximately 180 patients on reimbursed commercial therapy in the United States.

Ultragenyx reported total revenue of $91.5 million for the fourth quarter of 2020. The company had a net loss of $24.0 million, or $0.37 per share. They reaffirmed the 2021 guidance range for Crysvita of $180 million to $190 million.

Ultragenyx reported Q3 2020 total revenue of $81.5 million, driven by Crysvita revenue of $37.3 million. The company has increased the lower end of Crysvita guidance range; updated full year range is $130 million to $140 million. Dojolvi launch is off to a strong start.

Ultragenyx reported a total revenue of $61.7 million for the second quarter of 2020, including Crysvita revenue in Ultragenyx territories of $32.4 million. The company also had two FDA approvals in the second quarter and maintained its full-year 2020 guidance.

Ultragenyx reported first quarter 2020 financial results, with total revenue of $36.3 million. The company maintains full year 2020 guidance based on COVID-19 impact to date. The FDA reviews for Crysvita for TIO and UX007 for LC-FAOD are on track to be completed in the coming months.

Ultragenyx reported total revenue of $35.6 million for the fourth quarter of 2019. The company's net loss for the quarter was $93.8 million, or $1.62 per share.